ClinicalTrials.gg
CompletedNCT00058539Updated Jun 23, 2015Results posted

Safety and Efficacy Study of Pertuzumab to Treat Castration-Resistant Prostate Cancer

A Phase 2 interventional study of rhuMAb 2C4 (pertuzumab) in Prostate Cancer, sponsored by Genentech, Inc.. Completed. Open to male participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2015-06-23.

Sponsored by Genentech, Inc. (part of Hoffmann-La Roche) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
42
Allocation
Non-randomized
Ages
18 Years and older
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 11 studies in Prostatic Neoplasms by Hoffmann-La Roche — 3 open to participants now, 3 under way, none of them phase 3. Prostatic Neoplasms · Hoffmann-La Roche.

Enrollment
10th of 11
42 · median 84
Started
2003
with 1 other
Phase 2
3 of 11
1 open now
Registered
1st of 11
by date

Among the 11 studies in Prostatic Neoplasms by Hoffmann-La Roche, this one is the 10th largest by enrollment, is one of 2 that started in 2003, is one of 3 in phase 2, and was the 1st registered.

Prostatic Neoplasms

7,051 studies on the registry are indexed under Prostatic Neoplasms; 1,582 are open to participants now.

Browse Prostatic Neoplasms studies →

Open to participants now

3 of the 11 studies in Prostatic Neoplasms by Hoffmann-La Roche are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

Who these studies take

Of the 1,230 Prostatic Neoplasms studies recruiting now, 929 (76%) set no upper age limit and 76 (6%) stop at 75 or younger; 67 take children under 18; 82 take healthy volunteers.

This study: 18 Years and older · male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 11 studies in Prostatic Neoplasms by Hoffmann-La Roche, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate safety and efficacy of Omnitarg (Pertuzumab) on cancerous lesions in men with castration-resistant (hormone-refractory) prostate cancer.

03

Conditions studied

  • Prostate Cancer

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Signed
  • Age >= 18 years old
  • documented adenocarcinoma of the prostate, clinically or resistant to hormone therapy, as assessed by progression following at least one hormonal therapy (orchiectomy or luteinizing hormone-releasing hormone [LHRH] agonist). Subjects must have documented progression following hormonal therapy withdrawal of >= 4 weeks duration; nilutamide and bicalutamide require 6 weeks withdrawal.
  • Progression of disease after one prior chemotherapy regimen (which must have been taxane-based) for CRPC. Progression is defined as at least one of the following: A minimum of three consecutive serum PSA measurements obtained >= 14 days apart and all within 3 months, with progressively increasing values for two consecutive measurements. The latest value must be obtained within the screening period and must be >= 5 ng/mL; or progression of , as defined by ; or progression of bone disease, as defined by the appearance of one or more new bone lesions
  • Orchiectomy, or castrate levels of testosterone maintained by LHRH agonist \<70 ng/mL
  • >= 12 weeks
  • performance status of 0 or 1
  • Granulocyte count of >= 1500/mL, count of >= 75,000/mL and of >= 9 g/dL (hemoglobin may be supported by transfusion or erythropoietin or other approved hematopoietic growth factors; darbopoeitin [Aranesp] is permitted)
  • Serum less than or equal to the (ULN), unless due to Gilbert's disease, and alkaline phosphatase, , and ALT \<= 2.5 x ULN (ALT, AST, and alkaline phosphatase \<= 5 x ULN for subjects with liver ; no alkaline phosphatase upper limit for subjects with bone metastases)
  • Serum creatinine \<= 1.5 x ULN
  • (INR) \<1.5 and activated partial thromboplastin time (aPTT) \<1.5 x ULN (except for subjects receiving warfarin)
  • Willing to complete serial PROSQOLI/PPI evaluations and serial diaries of analgesic use (if necessary)

Exclusion criteria

Exclusion Criteria:

  • Prior chemotherapy, radiotherapy, therapeutic radionucleotide or immunotherapy within 4 weeks of Day 1 (the day of the first rhuMAb 2C4 dose). Flutamide therapy, or other hormonal therapies should be withdrawn >= 4 weeks prior to Day 1. Bicalutamide and nilutamide therapy should be withdrawn >= 6 weeks prior to starting study medication.
  • Prior treatment with pathway inhibitors (e.g., Herceptin [Trastuzumab], Iressa [gefitinib], Tarceva [erlotinib hydrochloride], C225, CI1033, and TAK165)
  • Treatment with other experimental anticancer agents within 4 weeks prior to Day 1
  • Prior history or clinical evidence of central nervous system or
  • , determined by ECHO, \<50%
  • Uncontrolled hypercalcemia (>11.5 mg/dL)
  • Prior exposure of >360 mg/m2 doxorubicin, >120 mg/m2 mitoxantrone, or >90 mg/m2 idarubicin
  • Ongoing treatment, except for subjects who are on stable doses of \<20 mg of prednisone daily (or equivalent), or who are taking corticosteroids for reasons unrelated to prostate cancer
  • History of other within 5 years prior to Day 1, except for adequately treated basal or squamous cell skin cancer
  • History of serious systemic disease, including active infection, uncontrolled hypertension (diastolic blood pressure >100 mmHg on two consecutive occasions), unstable angina, congestive heart failure, or myocardial infarction within 6 months prior to Day 1, or unstable symptomatic arrhythmia requiring medication (subjects with chronic atrial arrhythmia, i.e., atrial fibrillation, paroxysmal supraventricular tachycardia, or controlled hypertension are eligible)
  • Ongoing liver disease, including viral or other hepatitis, current alcohol abuse, or cirrhosis
  • Known infection
  • Major surgery or significant traumatic injury within 3 weeks prior to Day 1
  • Inability to comply with study and follow-up procedures
  • Any other diseases, metabolic dysfunction, physical examination finding, or clinical laboratory finding giving reasonable suspicion of a disease or condition that contraindicates the use of an drug or that may affect the interpretation of the results or render the subject at high risk for treatment complications
Terms in these criteria, in plain language(22)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
42 participants (actual)

Interventions

06

What researchers measure

Primary outcomes

  1. Percentage of Participants With a Best Overall Confirmed Response of Complete Response (CR) or Partial Response (PR) Based on Response Evaluation Criteria in Solid Tumors (RECIST) and Prostate Specific Antigen (PSA) Response Rate Based on Bubley Criteria

    Response by tumor measurement occurred if there was documented and confirmed CR or PR. Response was assessed by both the RECIST and by PSA levels measurement, based on measurable or non-measurable disease at baseline. Per RECIST, CR: disappearance of all target and non-target lesions and normalization of tumor marker level; PR: at least a 30 percent (%) decrease in the sum of the longest diameter of target lesions, taking as reference the baseline sum of longest diameter. A PSA response was defined as a PSA decline of greater than or equal to (≥) 50%, which had to be confirmed by a second PSA value at least 4 weeks later.

    Time frame: Screening, Day 1 of Cycles 1-17, and at 30 days after the last dose of pertuzumab

  2. Kaplan Meier Estimate of Percentage of Participants With Disease Progression at 3 Months

    Per RECIST, disease progression was defined as at least a 20% increase in the sum of the longest diameter of target lesions, taking as reference the smallest sum of longest diameter recorded since the treatment started or the appearance of 1 or more new lesions, and/or unequivocal progression of existing non-target lesions.

    Time frame: 3 months

Secondary outcomes

  1. Percentage of Participants With Disease Progression or Death (Progression Free Survival [PFS])

    PFS was defined as the time from the first day of study drug treatment to the time of documented disease progression or death, whichever came first. Participants who were lost to follow-up or who had not progressed at the time of study completion or early termination were censored at the date of last tumor assessment. The percentage of participants experiencing disease progression or death was calculated as the number of participants with an event divided by the number of participants analyzed, multiplied by 100.

    Time frame: Screening, Day 1 of Cycles 1-17, and at 30 days after the last dose of pertuzumab

  2. Median Time of PFS

    PFS was defined as the time from the first day of study drug treatment to the time of documented disease progression or death, whichever came first. Participants who were lost to follow-up or who had not progressed at the time of study completion or early termination were censored at the date of last tumor assessment.

    Time frame: Screening, Day 1 of Cycles 1-17, and at 30 days after the last dose of pertuzumab

  3. Duration of Response

    Duration of response was defined as the time from the initial CR or PR to the time of disease progression.

    Time frame: Screening, Day 1 of Cycles 1-17, and at 30 days after the last dose of pertuzumab

  4. Percentage of Participants Who Progressed at 3, 6 and 9 Months

    Per RECIST, disease progression was defined as at least a 20% increase in the sum of the longest diameter of target lesions, taking as reference the smallest sum of longest diameter recorded since the treatment started or the appearance of 1 or more new lesions, and/or unequivocal progression of existing non-target lesions. Percentage of participants who were free from disease progression was calculated by subtracting the number of participants with disease progression at that time point from the total population at risk of disease progression, multiplied by 100.

    Time frame: 3, 6, and 9 months

  5. Serum Concentrations of Pertuzumab

    Time frame: Assessed at pre-dose, 15-minutes postdose on Day 1 (Cycle 1), Day 22 (Cycle 2), Day 43 (Cycle 3), Day 85 (Cycle 5), and Day 169 (Cycle 9); pre-dose on Day 253 (Cycle 13), and on Days 8, 15, 29 and 36

07

Results

Posted Jun 23, 2015

Participant flow

Participant flow — Overall Study
MilestonePertuzumab
Started42
Completed0
Not completed42
Withdrew: Disease progression24
Withdrew: Adverse event3
Withdrew: Withdrawal by subject5
Withdrew: Physician decision9
Withdrew: Death1

Outcome measures

PrimaryPercentage of Participants With a Best Overall Confirmed Response of Complete Response (CR) or Partial Response (PR) Based on Response Evaluation Criteria in Solid Tumors (RECIST) and Prostate Specific Antigen (PSA) Response Rate Based on Bubley Criteria

Response by tumor measurement occurred if there was documented and confirmed CR or PR. Response was assessed by both the RECIST and by PSA levels measurement, based on measurable or non-measurable disease at baseline. Per RECIST, CR: disappearance of all target and non-target lesions and normalization of tumor marker level; PR: at least a 30 percent (%) decrease in the sum of the longest diameter of target lesions, taking as reference the baseline sum of longest diameter. A PSA response was defined as a PSA decline of greater than or equal to (≥) 50%, which had to be confirmed by a second PSA value at least 4 weeks later.

Time frame:
Screening, Day 1 of Cycles 1-17, and at 30 days after the last dose of pertuzumab
Reported as:
Number · percentage of participants
Percentage of Participants With a Best Overall Confirmed Response of Complete Response (CR) or Partial Response (PR) Based on Response Evaluation Criteria in Solid Tumors (RECIST) and Prostate Specific Antigen (PSA) Response Rate Based on Bubley Criteria
percentage of participantsPertuzumab
Percentage of Participants With a Best Overall Confirmed Response of Complete Response (CR) or Partial Response (PR) Based on Response Evaluation Criteria in Solid Tumors (RECIST) and Prostate Specific Antigen (PSA) Response Rate Based on Bubley Criteria0.0 (0.0 to 0.0)
PrimaryKaplan Meier Estimate of Percentage of Participants With Disease Progression at 3 Months

Per RECIST, disease progression was defined as at least a 20% increase in the sum of the longest diameter of target lesions, taking as reference the smallest sum of longest diameter recorded since the treatment started or the appearance of 1 or more new lesions, and/or unequivocal progression of existing non-target lesions.

Time frame:
3 months
Reported as:
Number · percentage of participants
Kaplan Meier Estimate of Percentage of Participants With Disease Progression at 3 Months
percentage of participantsPertuzumab
Kaplan Meier Estimate of Percentage of Participants With Disease Progression at 3 Months80
SecondaryPercentage of Participants With Disease Progression or Death (Progression Free Survival [PFS])

PFS was defined as the time from the first day of study drug treatment to the time of documented disease progression or death, whichever came first. Participants who were lost to follow-up or who had not progressed at the time of study completion or early termination were censored at the date of last tumor assessment. The percentage of participants experiencing disease progression or death was calculated as the number of participants with an event divided by the number of participants analyzed, multiplied by 100.

Time frame:
Screening, Day 1 of Cycles 1-17, and at 30 days after the last dose of pertuzumab
Reported as:
Number · percentage of participants
Percentage of Participants With Disease Progression or Death (Progression Free Survival [PFS])
percentage of participantsPertuzumab
Percentage of Participants With Disease Progression or Death (Progression Free Survival [PFS])83.3
SecondaryMedian Time of PFS

PFS was defined as the time from the first day of study drug treatment to the time of documented disease progression or death, whichever came first. Participants who were lost to follow-up or who had not progressed at the time of study completion or early termination were censored at the date of last tumor assessment.

Time frame:
Screening, Day 1 of Cycles 1-17, and at 30 days after the last dose of pertuzumab
Reported as:
Median · weeks
Median Time of PFS
weeksPertuzumab
Median Time of PFS9.6 (9.1 to 11.1)
SecondaryDuration of Response

Duration of response was defined as the time from the initial CR or PR to the time of disease progression.

Time frame:
Screening, Day 1 of Cycles 1-17, and at 30 days after the last dose of pertuzumab

No measurements were reported for this outcome.

SecondaryPercentage of Participants Who Progressed at 3, 6 and 9 Months

Per RECIST, disease progression was defined as at least a 20% increase in the sum of the longest diameter of target lesions, taking as reference the smallest sum of longest diameter recorded since the treatment started or the appearance of 1 or more new lesions, and/or unequivocal progression of existing non-target lesions. Percentage of participants who were free from disease progression was calculated by subtracting the number of participants with disease progression at that time point from the total population at risk of disease progression, multiplied by 100.

Time frame:
3, 6, and 9 months
Reported as:
Number · percentage of participants
Percentage of Participants Who Progressed at 3, 6 and 9 Months
percentage of participantsPertuzumab
% of participants progressed at 3 months66.7
% of participants progressed at 6 months80.0
% of participants progressed at 9 months83.3
SecondarySerum Concentrations of Pertuzumab
Time frame:
Assessed at pre-dose, 15-minutes postdose on Day 1 (Cycle 1), Day 22 (Cycle 2), Day 43 (Cycle 3), Day 85 (Cycle 5), and Day 169 (Cycle 9); pre-dose on Day 253 (Cycle 13), and on Days 8, 15, 29 and 36
Reported as:
Mean · micrograms per milliliter (µg/mL)
Serum Concentrations of Pertuzumab
micrograms per milliliter (µg/mL)Pertuzumab
Day 1, 15 minutes postdose (n=38)254.71 ± 46.85
Day 8 (n=39)97.51 ± 25.93
Day 15 (n=38)69.23 ± 19.13
Day 22 pre-dose (n=33)52.41 ± 15.23
Day 22, 15 minutes postdose (n=31)175.87 ± 34.70
Day 29 (n=30)88.17 ± 27.83
Day 36 (n=32)67.45 ± 21.46
Day 43 pre-dose (n=26)53.09 ± 19.45
Day 43, 15 minutes postdose (n=23)176.17 ± 32.43
Day 85 pre-dose (n=5)67.36 ± 23.66
Day 85, 15 minutes postdose (n=4)199.50 ± 35.07
Day 169 pre-dose (n=3)75.97 ± 49.41
Day 169, 15 minutes postdose (n=3)207.67 ± 71.70
Day 253 pre-dose (n=1)40.7 ± NA

Adverse events

Collected over Adverse events were collected from baseline until up to 30 days after the last dose of pertuzumab.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Pertuzumab—11/41 (26.8%)39/41 (95.1%)
Most frequent serious events
Showing 10 of 16
Most frequent serious events
EventPertuzumab
Ureteric obstructionRenal and urinary disorders2/41
Bone painMusculoskeletal and connective tissue disorders2/41
ConstipationGastrointestinal disorders1/41
Duodenal ulcer haemorrhageGastrointestinal disorders1/41
IleusGastrointestinal disorders1/41
Bilateral hydronephrosisRenal and urinary disorders1/41
CellulitisInfections and infestations1/41
PneumoniaInfections and infestations1/41
TachycardiaCardiac disorders1/41
PainGeneral disorders1/41
Most frequent other events
Showing 10 of 38
Most frequent other events
EventPertuzumab
DiarrhoeaGastrointestinal disorders25/41
NauseaGastrointestinal disorders14/41
FatigueGeneral disorders14/41
ArthralgiaMusculoskeletal and connective tissue disorders13/41
Ejection fraction decreasedInvestigations12/41
AnorexiaMetabolism and nutrition disorders11/41
ConstipationGastrointestinal disorders8/41
VomitingGastrointestinal disorders8/41
Oedema peripheralGeneral disorders8/41
MyalgiaMusculoskeletal and connective tissue disorders7/41

Baseline characteristics

All the participants who received at least 1 dose of study drug were included in the analysis.

Age, Continuous
Age, Continuous(years)Pertuzumab
Mean67.7 ± 8.8
Sex: Female, Male
Sex: Female, Male(Participants)Pertuzumab
Female0
Male41
08

Study locations

No study locations are listed for this record.

09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Apr 2003, a primary completion of Oct 2004 and a completion of Oct 2004. It does not say whether these dates are actual or estimated.

Results were first posted in Jun 2015, 10 years 8 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 8, 2003
First posted
Apr 9, 2003
Start
Apr 2003
Primary completionActual
Oct 2004
CompletionActual
Oct 2004
Results first posted
Jun 23, 2015
Last update
Jun 23, 2015
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 23, 2015, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00058539
Lead sponsor
Genentech, Inc.
First posted
Apr 9, 2003
Start date
Apr 2003
Primary completion
Oct 2004
Completion
Oct 2004
Results posted
Jun 23, 2015
Last update
Jun 23, 2015
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2015. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Pertuzumab

Start the discussion